Wegovy pill price lures UK patients off Mounjaro but weight loss can stall
A UK patient who swapped Mounjaro for the cheaper Wegovy pill regained weight. Trial figures cited by doctors show the tablet does less on average, and lower doses may do less still.
Who feels it
-
Patients
Rethink
A cheaper pill may mean less weight loss, especially at low doses or if fasting rules and daily doses slip.
-
Prescribers
Adjust
Patients switching on price need clear advice on dose, empty stomach timing and realistic expectations.
-
Pharmacies
Adjust
Private buyers are moving between Mounjaro, Wegovy pens and the tablet as prices shift.
-
Payers
Worth knowing
NHS use of the tablet waits on a NICE evaluation, so private patients carry the cost for now.
-
Sellers
Worth knowing
Promotion that implies the pill matches the jabs can mislead patients about expected results.
The Wegovy pill price has drawn some UK patients away from weight loss injections, but a cheaper monthly bill can bring slower results. A Daily Mail report published on 6 November follows an Essex woman who left Mounjaro on cost grounds, moved to the semaglutide tablet to save more, and then regained weight. Doctors quoted in the piece say the tablet is less potent than the jabs and harder to take correctly. Here is what the report shows about cost, effect and the choice facing people who pay privately.
Mounjaro UK price pushed one patient down the cost ladder
Allie Hudson, a 42 year old early years practitioner from Harlow in Essex, told the Daily Mail her weight has been a battle since she was a teenager. After a privately funded bariatric operation in Turkey took off about six stone, she started Mounjaro last year to reach a goal of 10 stone. She said she paid £160 a month through an online pharmacy. Soon after she began, Eli Lilly raised its UK private price and her monthly bill went above £200, according to the paper. The Mounjaro UK price rise hit private buyers, while NHS prices were held under a separate agreement. The newspaper cites a recent survey that found four in ten users quit the jab after the rise, but it does not name the survey or say how many people took part.
Her next step was the Wegovy injection, which she said cost £149 a month. This summer she moved again, to the Wegovy pill, which contains semaglutide, the same active drug as the injection. The report says some providers charge under £100 a month for lower doses of the tablet, while Mounjaro typically costs around £300. Ms Hudson said promotional articles had led her to believe the pills worked as well as the jabs. Within weeks she gained 6lb, and her weight has since stayed in a narrow band from 11st 9lb to 11st 12lb, she said. Last week she decided to return to Wegovy injections despite the higher cost. She told the paper she is now so close to her goal that she cannot quit.
Why the cheaper pill may do less
The core issue is strength. The Daily Mail puts average weight loss at around 20 per cent of body weight for Mounjaro and roughly 15 per cent for the Wegovy injection. For the tablet, the paper says trial participants given the top dose shed about 14 per cent. Lower doses cost less, and the report expects many patients to be on them, which could leave their results below that top trial figure. Taking the tablet properly is also demanding. According to the report, it needs a truly empty stomach and only a small amount of water, and then food has to wait for half an hour. When those steps slip, less of the drug may reach the bloodstream and its effect on appetite weakens.
Lower doses cost less, and the report expects many patients to be on them, which could leave their results below that top trial figure.
Naveed Sattar, a professor at the University of Glasgow, told the paper that the jabs are "a bit stronger", so patients who swap may notice their appetite rise. He added that skipping the fasting step or the water, or forgetting tablets "even occasionally", could cut the effect further. Ms Hudson said she missed doses a few times and found a once weekly injection easier to remember than a daily pill. That point matters for cost as well as results. A cheaper drug that is taken less reliably may deliver less weight loss for each pound spent. No study cited in the report measured that directly for UK private buyers, so the size of the gap in everyday use is unknown.
Weight loss jabs vs pills by the numbers
The table below sets out the figures the report gives on weight loss jabs vs pills. The prices are private monthly amounts quoted by the newspaper or paid by Ms Hudson, not official list prices, and they change with dose and provider. The weight loss figures are averages from separate trials, so they are not a head to head comparison, and the people enrolled in each study differed. Even so, the direction is clear. On average effect, the tablet sits a little below the Wegovy injection and well below Mounjaro, while its lowest doses sit at the bottom of the private price range. Readers weighing the Wegovy pill price against a jab are, in effect, trading some expected weight loss for a smaller bill.
| Option | Monthly cost cited in the report | Average weight loss cited |
|---|---|---|
| Mounjaro injection | Typically around £300; Ms Hudson paid £160, then over £200 | Around 20 per cent |
| Wegovy injection | £149 paid by Ms Hudson | About 15 per cent |
| Wegovy pill | Under £100 at some providers for lower doses | About 14 per cent at the highest dose in trials |
Scale explains why this matters. By the paper's estimate, roughly 2.5 million UK residents have had a prescription for a weight loss drug like Mounjaro or Wegovy, and most of them pay privately. NHS access remains narrow. In Scotland, a BBC survey found only 705 patients treated for weight loss through small pilots three years after approval. When most people pay out of pocket, each price move pushes some of them to switch drugs, drop to a lower dose or stop. The experts quoted by the paper expect that thousands who switched to save money have seen progress stall or reverse. The report gives no count of how many people actually switched, and the Wegovy pill price itself varies by dose and provider.
GLP 1 weight regain and what switchers can do
Specialists quoted in the report suggest several steps for people on the tablet. The first is food: more fibre from beans, lentils, vegetables and fruit, more protein such as fish and lean meat, and fewer sugary or processed foods. Enough sleep also helps, because short sleep can disturb appetite hormones and raise hunger. Regular exercise is the third step, and the report says research shows strength training is best for keeping weight off, though walking also counts as staying active. Ms Hudson said she lacks time, with two children and a job that keeps her on her feet all day. These habits support the medicine but do not replace it. Anyone thinking about switching should discuss dose, timing and expectations with the prescriber.
Regulators have approved both routes. The MHRA cleared the Wegovy tablet for weight management in June as the first GLP 1 tablet for weight loss in the UK, and Medscape reported that NHS use waits on a NICE evaluation. For now, the Wegovy pill price is paid privately. Stopping or weakening treatment also raises the wider problem of GLP 1 weight regain, since health systems fund the drugs but have not built the care that follows when weight returns. Several things remain unknown: how many UK patients switched to save money, whether private tablet prices will hold, and how routine results compare with trials. One patient's story shows a risk; it does not measure how common that risk is.
Conclusion
The Wegovy pill price makes oral semaglutide the cheapest private GLP 1 option cited in this report, but the figures it quotes show less average weight loss than either injection, and lower doses may deliver less still. The tablet also depends on strict daily habits. For people paying out of pocket, the real cost is the monthly bill measured against the weight loss it buys. Patients considering a switch should review dose, timing and goals with a prescriber first. This story is for information only and is not medical advice.
Source Daily Mail Health, 6 November 2026, patient account and expert comment; MHRA approval of the Wegovy tablet as reported by Medscape, June 2026
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.